Most, but not all cross-sectional surveys have identified lower quality of life among patients with hypertension. We summarized the estimates for this association in a systematic review and in a meta-analysis of cross-sectional studies. Studies that used the Short-Form Health Survey (SF) to compare the quality of life of normotensive and hypertensive individuals were searched in Embase, MEDLINE/PubMed, LILACS, Ovid, ScienceDirect, SciELO and Cochrane databases using 'hypertension' and 'quality of life' medical subject heading (MeSH) terms and the words 'health survey, SF-12, SF-36 and their spelling variations (SF12, SF 12, SF36 and SF 36)'. Data extraction was conducted by two researchers. Data were analyzed with MIX 1.7 using random effects model. Results of the meta-analysis were expressed as differences of mean scores between hypertensive and normotensive individuals. Most of the 20 studies selected for the systematic review identified lower quality of life in patients with hypertension, but they were very heterogeneous in regard to selection criteria and comparison groups, limiting their external validity. The meta-analysis identified lower scores in hypertensive patients for physical [-2.43; 95% confidence interval (CI) -4.77 to -0.08] and mental (-1.68; 95% CI -2.14 to -1.23) components. Quality of life was lower in the eight domains of the SF-36: physical and functional functioning, role physical and emotional, bodily pain, general health, vitality and mental health. Quality of life of individuals with hypertension is slightly worse than that of normotensive individuals. The influence of high blood pressure and of the awareness to have hypertension requires further investigation.
OBJECTIVE: To examine the relationship between gastroesophageal reflux (GER) and COPD exacerbations. METHODS: We conducted a systematic search of various electronic databases for articles published up through December of 2012. Studies considered eligible for inclusion were those dealing with COPD, COPD exacerbations, and GER; comparing at least two groups (COPD vs. controls or GER vs. controls); and describing relative risks (RRs) and prevalence ratios-or ORs and their respective 95% CIs (or presenting enough data to allow further calculations) for the association between GER and COPD-as well as exacerbation rates. Using a standardized form, we extracted data related to the study design; criteria for GER diagnosis; age, gender, and number of participants; randomization method; severity scores; methods of evaluating GER symptoms; criteria for defining exacerbations; exacerbation rates (hospitalizations, ER visits, unscheduled clinic visits, prednisone use, and antibiotic use); GER symptoms in COPD group vs. controls; mean number of COPD exacerbations (with symptoms vs. without symptoms); annual frequency of exacerbations; GER treatment; and severity of airflow obstruction. RESULTS: Overall, GER was clearly identified as a risk factor for COPD exacerbations (RR = 7.57; 95% CI: 3.84-14.94), with an increased mean number of exacerbations per year (mean difference: 0.79; 95% CI: 0.22-1.36). The prevalence of GER was significantly higher in patients with COPD than in those without (RR = 13.06; 95% CI: 3.64-46.87; p < 0.001). CONCLUSIONS: GER is a risk factor for COPD exacerbations. The role of GER in COPD management should be studied in greater detail.
10 May 2013 in Revista da Sociedade Brasileira de Medicina Tropical